Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402478 | 0.86 | KDM4E (0.44) | KDM4ELMNAHPGDALDH1A1EIF4A3 | |
| SCHEMBL6400705 | 0.84 | TP53 (0.60) | KDM4ENHERF1HPGDALDH1A1TP53 | |
| SCHEMBL6399999 | 0.82 | NHERF1 (0.63) | KDM4ENHERF1EGFR | |
| SCHEMBL6400350 | 0.82 | FLT3 (0.54) | KDM4ELMNAHPGDALDH1A1 | |
| SCHEMBL6405426 | 0.82 | BCAT1 (0.59) | KDM4ENHERF1GAAALDH1A1MAPK1 | |
| SCHEMBL6401839 | 0.81 | KDM4E (0.56) | KDM4ENHERF1GAAHPGDALDH1A1 | |
| SCHEMBL6404295 | 0.80 | BCAT1 (0.59) | KDM4E | |
| SCHEMBL20381090 | 0.77 | TP53 (0.70) | NHERF1EGFRPIK3CALMNATP53 | |
| SCHEMBL6399671 | 0.76 | TP53 (0.53) | TP53POLB | |
| SCHEMBL6405483 | 0.76 | TP53 (0.50) | KDM4ETP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | FADS1 2178/4885KDM4E 1617/4885NHERF1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.